provides that a manufacturer who sells covered outpatient drugs to eligible (covered) entities must sign a pharmaceutical pricing agreement with the Secretary of HHS in which the manufacturer agrees to charge a price for covered outpatient drugs that will not exceed that amount determined under a statutory formula.

The purpose of this notice is to withdraw the **Federal Register** notice entitled, ''Notice Regarding Section 602 of the Veterans Health Care Act of l992—Rebate Mechanism,'' published on March 14, l997. This notice requested comments on the proposal of a rebate process for State AIDS Drug Assistance Programs receiving funds under Title XXVI of the PHS Act.

FOR FURTHER INFORMATION CONTACT: Annette Byrne, R. Ph., Director, Office of Drug Pricing, Bureau of Primary Health Care, Health Resources and Services Administration, 4350 East West Highway, 10th Floor, Bethesda, MD 20814, Phone (301) 594–4353, Fax (301) 594–4982.

SUPPLEMENTARY INFORMATION: HRSA guidance for the section 340B drug program has described only a discount process for accessing 340B pricing. Although this discount system is functioning successfully for most covered entities, some State AIDS Drug Assistance Programs (ADAPs) have drug purchasing systems that have prevented their participation in the 340B drug program. The use of a rebate mechanism (in addition to the discount mechanism) should allow these groups to access 340B pricing.

Because the rebate mechanism is only a part of a larger endeavor by HRSA to develop the 340B drug program in such a manner as to effectively reach all covered entities, the notice outlining the concept of a narrowly-focused rebate mechanism is withdrawn for further internal deliberation.

Dated: March 14, 1997.

Ciro V. Sumaya,

Administrator.

[FR Doc. 97–7142 Filed 3–20–97; 8:45 am]

BILLING CODE 4160–15–P

National Institutes of Health

Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Advisory Committee on Blood Safety and Availability, Department of Health and Human Services, March 20–21, 1997, which was published in the **Federal Register** on March 3, 1997 (62 FR 9441).

This meeting will be held on April 24–25, 1997, instead of the previously stated March 20–21. The Advisory meeting remains at the same time and place, 8:30 a.m., National Institutes of Health, Warren G. Magnuson Clinical Center, Jack Masur Auditorium, 9000 Rockville Pike, Bethesda, Maryland 20892. As previously stated, this meeting will be entirely open to the public.

On April 24, the Committee will discuss hepatitis C virus (HCV) infection, its occurrence following blood transfusion, other epidemiology of HCV infection and appropriate ways of approaching the public health aspects of this infection. On April 25, the Committee will address multiple aspects of the theoretical possibility that Creutzfeldt-Jakob disease (CJD) can be transmitted by blood transfusion. For each topic, a time will be set aside for the public to comment. Prospective speakers should notify the Executive Secretary for this meeting of their wish to present and should plan for no more than 5 minutes of comments.

CONTACT: Paul R. McCurdy, M.D., Acting Executive Secretary, Advisory Committee on Blood Safety and Availability, Director, Blood Resources Program, DBDR–MSC–7950, NHLBI, NIH, Bethesda, Maryland 20892–7950. *Phone:* 301/435–0065; Fax 301/480–1060; *E-Mail:* paul__mccurdy@nih.gov.

Dated: March 17, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–7129 Filed 3–20–97; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institutes; Notice of Meeting

Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the following National Heart, Lung, and Blood Institutes Special Emphasis Panel.

The meeting will be open to the public to provide concept review of proposed contract or grant solicitations.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should inform the Contract Person listed below in advance of the meeting.

Name of Panel: Stem Cell Transplantation in Sickle Cell Disease.

Dates of Meeting: April 30, 1997.

Time of Meeting: 10:00 a.m.

Place of Meeting: Two Rockledge Center, Rm. 9112, 6701 Rockledge Drive, Bethesda, Maryland 20892.

Agenda: To review current progress and identify future initiatives in the use of stem cell transplantation for the treatment of sickle cell disease.

Contact Person: Helena Mishoe, Ph.D., NHLBI/DBDR, Two Rockledge Center, 6701 Rockledge Drive, Rm. 10156, MSC 7950, Bethesda, Maryland 20892, (301) 435–0050.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: March 17, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–7128 Filed 3–20–97; 8:45 am]

BILLING CODE 4140–01–M

Prospective Grant of Exclusive License: Replicating Tumoricidal Viral Therapy for Cancer Applications

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive license worldwide to practice the invention embodied in U.S. Patent Application Number 07/725,076 (issued on October 25, 1994 as U.S. Patent No. 5,358,866) entitled ''Cytosine Deaminase Negative Selection System for Gene Transfer Techniques and Therapies'' and its divisional applications 08/271,874, 08/447,580, 08/447,393, 08/445,203, 08/447,487, 08/449,627, 08/448,867, 08/449,636, and all related foreign filings, to ONYX, Inc., having a place of business in Richmond, CA (USA). The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. This notice modifies a previous notice of April 11, 1996 found in Volume 61, Number 71 of the **Federal Register**.

The field of use would be limited to Replicating Tumoricidal Viral Therapy for Cancer applications.

The present inventions relate to a modified bacterial gene for cytosine deaminase. Specifically, the CD gene can be used as a negative selectable